New analyses on the genomic architecture of T2D & contribution of rare variation, with lessons for rare variant studies. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls nature nature.com/articles/s4158… Congrats J Flannick Mark McCarthy Noel Burtt et al!

Our new study of coding variants and T2D shows that rare variants contribute less to T2D than we thought a decade ago, but may be more useful than we thought three years ago: nature.com/articles/s4158… @T2DKP Noel Burtt

Was reviewing some work on genetics + drug targets and found these to be of interest: ncbi.nlm.nih.gov/pubmed/30952858 and biorxiv.org/content/10.110…

In particular (1) coding GWAS variants seem to increase likelihood of success even more than the two-fold reported earlier for arbitrary GWAS

And (2) solid evidence that toxicity can be predicted as well (well-done analysis in this one as well)

The @T2DKP is hosting an ancillary event at #ASHG19 Foundational Resources for Translating Genetic Associations to Function & Targets! Come join the discussion & demo, Wednesday, Oct. 16, 12:45. Details 👇

Looking forward to #ASHG19. If you are attending and interested in postdoc opportunities in exome analysis or integrative computational genomics, message me and we can chat about opportunities in flannicklab.org.

Is a p=0.02 association real or not? It depends on the gene. See Lokendra Thakur talk about our method for gene prior calculations at #ASHG19 Room 371A/4:45pm

Interested in scientific software & methods for moving for complex disease associations to targets? Come talk with Jason Flannick Jason Flannick at the Broad Clinical Labs booth tomorrow👇

What can 45,000 exomes tell you about GWAS and core genes? Come ask the always classy Peter Dornbos from 2-3PM at #ASHG19 poster 2804